{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:42:25Z","timestamp":1768556545062,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NEI P30-EY026877"],"award-info":[{"award-number":["NEI P30-EY026877"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","aaojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ophtha.2024.07.034","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T17:15:33Z","timestamp":1722964533000},"page":"219-227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ocular Neovascular Conversion and Systemic Bleeding Complications in Patients with Age-Related Macular Degeneration on Anticoagulants"],"prefix":"10.1016","volume":"132","author":[{"given":"Amer F.","family":"Alsoudi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-3338","authenticated-orcid":false,"given":"Euna","family":"Koo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Wai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1087-9736","authenticated-orcid":false,"given":"Prithvi","family":"Mruthyunjaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ehsan","family":"Rahimy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"22","key":"10.1016\/j.ophtha.2024.07.034_bib1","doi-asserted-by":"crossref","first-page":"e026723","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.ophtha.2024.07.034_bib2","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.amjmed.2015.05.044","article-title":"National trends in ambulatory oral anticoagulant use","volume":"128","author":"Barnes","year":"2015","journal-title":"Am J Med"},{"issue":"18","key":"10.1016\/j.ophtha.2024.07.034_bib3","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.ophtha.2024.07.034_bib4","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.ophtha.2024.07.034_bib5","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.ophtha.2024.07.034_bib6","article-title":"Efficacy and safety of direct oral anticoagulants for stroke prevention in older patients with atrial fibrillation: a network meta-analysis of randomized controlled trials","volume":"12","author":"Lin","year":"2023","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ophtha.2024.07.034_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12325-022-02333-9","article-title":"Risk and management of bleeding complications with direct oral anticoagulants in patients with atrial fibrillation and venous thromboembolism: a narrative review","volume":"40","author":"Ballestri","year":"2023","journal-title":"Adv Ther"},{"issue":"10","key":"10.1016\/j.ophtha.2024.07.034_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.ophtha.2024.07.034_bib9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.ophtha.2024.07.034_bib10","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ophtha.2024.07.034_bib11","doi-asserted-by":"crossref","first-page":"614","DOI":"10.3109\/08820538.2016.1139738","article-title":"Ophthalmic complications associated with direct oral anticoagulant medications","volume":"32","author":"Shieh","year":"2017","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2024.07.034_bib12","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1001\/jamaophthalmol.2017.5677","article-title":"Association of novel oral antithrombotics with the risk of intraocular bleeding","volume":"136","author":"Uyhazi","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"23","key":"10.1016\/j.ophtha.2024.07.034_bib13","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ophtha.2024.07.034_bib14","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1001\/jamaophthalmol.2017.2199","article-title":"Risk of intraocular bleeding with novel oral anticoagulants compared with warfarin","volume":"135","author":"Sun","year":"2017","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"10.1016\/j.ophtha.2024.07.034_bib15","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/jamaophthalmol.2015.2069","article-title":"Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage","volume":"133","author":"Jun","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"10.1016\/j.ophtha.2024.07.034_bib16","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/eye.2016.265","article-title":"Risk of intraocular hemorrhage with new oral anticoagulants","volume":"31","author":"Talany","year":"2017","journal-title":"Eye"},{"issue":"2","key":"10.1016\/j.ophtha.2024.07.034_bib17","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ajo.2009.08.033","article-title":"Subretinal hemorrhages associated with age-related macular degeneration in patients receiving anticoagulation or antiplatelet therapy","volume":"149","author":"Kuhli-Hattenbach","year":"2010","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2024.07.034_bib18","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s00347-012-2567-2","article-title":"Submakul\u00e4re Massenblutung und Gerinnungshemmer","volume":"109","author":"Kuhli-Hattenbach","year":"2012","journal-title":"Ophthalmologe"},{"issue":"6","key":"10.1016\/j.ophtha.2024.07.034_bib19","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/PL00007887","article-title":"Relationship between anticoagulant medication and massive intraocular hemorrhage in age-related macular degeneration","volume":"238","author":"Tilanus","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2024.07.034_bib20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF02172720","article-title":"Massive intraocular hemorrhage associated with anticoagulation and age-related macular degeneration","volume":"226","author":"Lewis","year":"1988","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2024.07.034_bib21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3928\/23258160-20130909-06","article-title":"Association between systemic anticoagulation and rate of intraocular hemorrhage following intravitreal anti-VEGF therapy for age-related macular degeneration","volume":"44","author":"Olson","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"16","key":"10.1016\/j.ophtha.2024.07.034_bib22","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1001\/jama.1991.03470160111044","article-title":"Macular degeneration: is aspirin a risk for progressive disease","volume":"266","author":"Klein","year":"1991","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.ophtha.2024.07.034_bib23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ophtha.2015.09.046","article-title":"Association between antiplatelet or anticoagulant drugs and retinal or subretinal hemorrhage in the comparison of age-related macular degeneration treatments trials","volume":"123","author":"Ying","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.ophtha.2024.07.034_bib24","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex","volume":"145","author":"Carnicelli","year":"2022","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ophtha.2024.07.034_bib25","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLOS Med"},{"issue":"2","key":"10.1016\/j.ophtha.2024.07.034_bib26","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.ophtha.2014.08.020","article-title":"Outcomes of eyes with lesions composed of >50% blood in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)","volume":"122","author":"Altaweel","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2024.07.034_bib27","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2018.01.003","article-title":"Antiplatelet and anticoagulant drugs do not affect visual outcome in neovascular age-related macular degeneration in the BRAMD trial","volume":"187","author":"Buitendijk","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2024.07.034_bib28","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/heartjnl-2020-317887","article-title":"Discontinuation of oral anticoagulation in atrial fibrillation and risk of ischaemic stroke","volume":"107","author":"Rodr\u00edguez","year":"2021","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.ophtha.2024.07.034_bib29","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood-2013-12-512681","article-title":"Duration of anticoagulant therapy for deep vein thrombosis and pulmonary embolism","volume":"123","author":"Kearon","year":"2014","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ophtha.2024.07.034_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar Behav Res"},{"issue":"1","key":"10.1016\/j.ophtha.2024.07.034_bib31","article-title":"A\u00a0brief guide to decisions at each step of the propensity score matching process","volume":"21","author":"Harris","year":"2016","journal-title":"Pract Assess Res Eval"},{"issue":"1","key":"10.1016\/j.ophtha.2024.07.034_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"issue":"12","key":"10.1016\/j.ophtha.2024.07.034_bib33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.ophtha.2024.07.034_bib34","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s00417-022-05885-2","article-title":"Antiplatelet and anticoagulant therapy in patients with submacular hemorrhage caused by neovascular age-related macular degeneration","volume":"261","author":"Weber","year":"2023","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2024.07.034_bib35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"8","key":"10.1016\/j.ophtha.2024.07.034_bib36","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.18632\/oncotarget.23241","article-title":"Uncovering genetic and non-genetic biomarkers specific for exudative age-related macular degeneration: significant association of twelve variants","volume":"9","author":"Cascella","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ophtha.2024.07.034_bib37","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.preteyeres.2017.11.004","article-title":"Towards the application of precision medicine in age-related macular degeneration","volume":"63","author":"Cascella","year":"2018","journal-title":"Prog Retin Eye Res"},{"issue":"5","key":"10.1016\/j.ophtha.2024.07.034_bib38","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/jamaophthalmol.2018.0504","article-title":"Incidence of and risk factors associated with age-related macular degeneration: four-year follow-up from the ALIENOR Study","volume":"136","author":"Saunier","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2024.07.034_bib39","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1097\/IAE.0b013e3181b1baeb","article-title":"Risk factors for second eye progression to advanced age-related macular degeneration: SST report No. 21 Submacular Surgery Trials Research Group","volume":"29","author":"Solomon","year":"2009","journal-title":"Retina Phila Pa"},{"issue":"7","key":"10.1016\/j.ophtha.2024.07.034_bib40","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1001\/jamaophthalmol.2019.0868","article-title":"Imaging, genetic, and demographic factors associated with conversion to neovascular age-related macular degeneration","volume":"137","author":"Hallak","year":"2019","journal-title":"JAMA Ophthalmol"},{"issue":"S256","key":"10.1016\/j.ophtha.2024.07.034_bib41","doi-asserted-by":"crossref","DOI":"10.1111\/j.1755-3768.2016.0606","article-title":"Warfarin use among wet AMD patients","volume":"94","author":"Paterno","year":"2016","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"7","key":"10.1016\/j.ophtha.2024.07.034_bib42","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaophthalmol.2022.1640","article-title":"Long-term outcomes of adding lutein\/zeaxanthin and \u03c9-3 fatty acids to the AREDS supplements on age-related macular degeneration progression: AREDS2 Report 28","volume":"140","author":"Chew","year":"2022","journal-title":"JAMA Ophthalmol"},{"issue":"19","key":"10.1016\/j.ophtha.2024.07.034_bib43","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1001\/jama.2013.4997","article-title":"Lutein\u00a0+ zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) Randomized Clinical Trial","volume":"309","year":"2013","journal-title":"JAMA"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024004597?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642024004597?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T21:38:10Z","timestamp":1737754690000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642024004597"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S0161642024004597"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.07.034","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular Neovascular Conversion and Systemic Bleeding Complications in Patients with Age-Related Macular Degeneration on Anticoagulants","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2024.07.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}